Radiotherapy-induced ADAM17 leads to treatment resistance
Introduction
Radiotherapy along with chemotherapy or surgery is the primary treatment regimen for locally advanced non-small cell lung cancer (NSCLC). However, the response rates and clinical outcomes are still disappointing, with the 5-year survival rate being only approximately 15 % (1-3). Ionizing radiation (IR) triggers multiple intracellular signaling processes as part of IR-induced stress responses that lead to the secretion of various para-and autocrine factors into the tumor microenvironment (4) (5) (6) . These secreted components generate de novo resistance mechanisms during the course of the treatment and at the same time represent interesting targets to sensitize for IR-induced cell killing (7) (8) (9) . Several studies have shown that targeting tumor-derived factors such as VEGF, PDGFA, TGF-β, MMP-13, SDF-1 counteract growth of carcinoma cells and sensitize them to irradiation (10) (11) (12) (13) (14) .
Growth and survival of NSCLC cells are often dependent on ectodomain shedding which includes the proteolytic cleavage of the extracellular part of membrane proteins primarily mediated by membrane-anchored metalloproteases, and results in release of various soluble growth factors and cytokines regulating cell proliferation and migration (15, 16) . ADAMs (a disintegrin and metalloproteinase) are membrane-associated metalloproteinases with modular design and complex multi-domain structure (17) . Most of the members of the ADAM family (13 out of 21 human ADAMs) have proteolytic activity, as well as domains with adhesive properties and a cytoplasmic domain involved in cell signaling (18) . They are actively associated with the process of proteolytic 'shedding' of membrane-bound proteins and hence the rapid modulation of key signals in the tumor microenvironment. ADAM-mediated shedding is both constitutive and inducible, depending on upstream kinase activation, intracellular Ca 2+ levels, membrane lipid composition and other experimental and natural stimuli (19, 20) .
Multiple resistance mechanisms in NSCLC have been linked to the epidermal growth factor receptor (EGFR), which has therefore been regarded as promising target for a combined
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Author Manuscript Published OnlineFirst on April 13, 2016; DOI: 10.1158/1078-0432.CCR- treatment modality. However, a recent phase III trial for patients with stage IIIA or IIIB NSCLC (RTOG 0617) demonstrated that solely addition of the EGFR-directed monoclonal antibody cetuximab to concurrent chemoradiation and consolidation treatment does not provide any added benefit for these patients (21) . Thus, additional inhibition of the EGFR is insufficient, which might be due to the heterogenous expression status of other ErbB receptor family members in NSCLC or the mutational status of EGFR downstream signaling entities such as K-ras (22) (23) (24) .
Increased ADAM17 expression in NSCLC is associated with aggressive progression and poor prognosis. ADAM17 regulates shedding of multiple key oncogenic growth factors, cytokines and adhesion molecules including ligands of ErbB family members (15, 16, 19, (25) (26) (27) (28) . Thus ADAM17 drives pleiotropic pathways and might therefore represent a more relevant target for a combined treatment modality in NSCLC.
Here we provide novel insights into activation of ADAM17 and subsequent ligand shedding in response to irradiation. We show for the first time that direct targeting of ADAM17 with a clinically relevant inhibitor sensitizes lung carcinoma cells in vitro and in vivo to IR and provide a sound rationale for positioning ADAM17 inhibitors as radiosensitizers to improve the treatment of NSCLC.
Materials and Methods

Cell culture, Compounds and Irradiation
The human NSCLC cell lines A549, NCI-H125, H460, Calu-3, Calu-6 and the human epidermoid carcinoma cell line A431 were cultured in RPMI1640 media supplemented with 10 % (v/v) fetal calf serum, 1 % (v/v) penicillin-streptomycin and 1 % (v/v) L-glutamine at 37°C in 5 % CO 2 . All cell culture media and supplements were obtained from Gibco (Life Technologies TMI-005 was dissolved in DMSO (10 mM stock) and further diluted with cell culture media.
N-acetyl-L-cysteine (Sigma Aldrich; A8199) was dissolved in PBS (10 mM stock). The furin convertase inhibitor Dec-RVKR-CMK (Enzo Life Sciences; ALX-260-022) was dissolved in PBS (5 mM stock). Cetuximab (Erbitux) was obtained from Merck KGaA (5 mg/ml stock solution for infusion) and was further diluted to 100 nM for in vitro experiments. Irradiation was performed using an Xstrahl 200 kV X-Ray unit at 100 cGy/min. To produce conditioned media, fetal calf serum-supplemented (FCS) or FCS-deficient cell culture media was applied to proliferating cells 1 hour prior to sham-treatment or irradiation, collected 24 hours thereafter and filtered through a 0.45 µm filter.
Cell proliferation and clonogenic cell survival assays
The proliferative activity of tumor cells was assessed in 96-well plates with the colorimetric alamarBlue assay (Biosource International, Camarillo, CA). Clonogenic cell survival was determined by the ability of single cells to form colonies in vitro as described in (29) . Dose enhancement factors (DEF) were calculated using α and β values for each survival curve.
Survival data were fitted by weighted, stratified, linear regression to obtain the linear and quadratic parameters (29) . The DEF values at 37 % and 10 % survival level were calculated using linear regression in IBM SPSS statistics 22. All assays were repeated as independent experiments at least thrice.
Tumor xenograft in nude mice and application of treatment regimes A549 (4 x 10 6 cells) were injected subcutaneously on the back of 4-to 6-week old CD1 athymic nude mice. Tumor volumes were determined from caliper measurements of tumor length (L) and width (l) according to the formula (L x l 2 )/2. Tumors were allowed to expand to a volume of 200 mm 3 (± 10 %) before treatment start. Tumors were sham-irradiated or irradiated using a customized shielding device with 3 × 1 Gy for 3 consecutive days. TMI-005
Research. (dissolved in 0.9 % NaCl, 0.5 % methylcellulose and 2 % Tween 80) was administered orally at 25 mg/kg twice daily with 10 hours apart for seven consecutive days. For combined treatment (sham)-irradiation was performed 1 hour after the first daily TMI-005 application on day 3 to day 5 of the TMI-005 schedule.
In vivo shedding experiments were performed on blood serum derived from locally irradiated A549-derived tumor xenografts. At a tumor volume of 400-500 mm 3 , tumors were shamirradiated or irradiated with 10 Gy. IR-treated animals were sacrificed 48 hours after treatment. Tumors were excised and blood serum was collected from heart-punctured animals following euthanasia. All in vivo experiments were performed according to the guidelines for the welfare and use of animals of the Veterinäramt Kanton Zürich, Switzerland.
Immunohistochemistry
Immunohistological endpoints were analyzed on paraffin-embedded blocks for MIB1/Ki-67 Viable areas of the whole tumor sections were quantified for specific ADAM17, ALCAM or Amphiregulin staining intensity. Each treatment group consisted of at least 4 animals and tumor sections were manually quantified for low, medium and high staining.
Statistical analysis
Statistical analyses were performed using GraphPad Prism (version 5 
Results
IR induces the secretion of multiple ADAM17 substrates
A semiquantitative differential large scale secretome analysis (>300 factors) was performed to identify auto-and paracrine factors that are secreted in response to IR. Using several growth factor-, chemo-and cytokine-specific antibody arrays, multiple, differentially secreted factors were identified in conditioned media (CM) derived from sham-irradiated and irradiated A549 lung adenocarcinoma cells, respectively ( Fig. 1A and Supplementary Methods and Table 1 ).
Detailed analysis of hits pointed towards a limited number of upstream effectors regulating IR-induced secretion of biologically active factors. Interestingly, several substrates of the metalloprotease ADAM17 were upregulated (see Supplementary Table 1 and Fig. 1A ), in particular Amphiregulin and ALCAM. Of note, lactate dehydrogenase (LDH) activity, a control marker for unspecific cytolysis, was not increased in response to irradiation ( Supplementary Fig. S1A ). Thus, no general protein leakage could be observed, indicating specific, IR-mediated secretion of these ADAM17 substrates. Based on the increased abundance of ADAM17 substrates, we investigated regulation of ADAM17 in response to IR in detail.
Research. To confirm IR-enhanced ADAM17 substrate secretion in additional cell lines (A549, H460, NCI-H125, CALU-3, CALU-6, all NSCLC and A431, vulval), ALCAM and Amphiregulindirected ELISA were used to determine these ADAM17 substrates in a quantitative way in supernatants of irradiated tumor cells. Significant upregulation of both ADAM17 substrates could be detected in the NSCLC cell lines A549 and NCI-H125, and to different magnitudes in the other cell lines (Fig. 1B) .
Enhanced secretion of these ADAM17 substrates could be due to IR-induced expression. S1B and S1C). Furthermore, protein levels of intracellular Amphiregulin and ALCAM in response to IR as determined in cell lysates did not change ( Supplementary Fig. S1D ).
To confirm these findings in vivo, we analyzed ALCAM secretion from irradiated A549-derived tumor xenografts in mice. Tumors and blood sera were harvested 48 hours after irradiation with 10 Gy. Ex vivo analysis of blood serum from mice with locally irradiated A549-derived tumor xenografts revealed significantly increased levels of ALCAM in comparison to ALCAM levels in blood serum from sham-irradiated mice (Fig. 1D) .
Unfortunately, Amphiregulin concentrations were below a minimal technically detectable concentration. Additionally, we also observed increased staining of both ALCAM and Amphiregulin in tumor sections derived from locally irradiated xenografts in comparison to sham-irradiated tumors ( Fig. 1E and 1F ). These results demonstrate that IR induces the secretion of multiple ADAM17 substrates across a panel of NSCLC cell lines and from A549-derived tumor xenografts.
IR induces posttranslational modification and activation of ADAM17
Research. To rule out the involvement of closely related ADAM10 in the regulatory process (30, 31) , both ADAM17 and ADAM10 activities were determined in response to irradiation.
Interestingly, irradiation only increased ADAM17 but not ADAM10 activity in a dosedependent way ( Fig. 2A) . ADAM17 activity steadily increased over 30 hours in response to irradiation (Fig. 2B) . As a control experiment, ADAM17 activity was determined in irradiated cells pretreated with the reactive oxygen scavenger N-acetyl cysteine (NAC). NAC completely attenuated IR-induced ADAM17 activity in both A549 and NCI-H125 cells while having no effect on its basal activity ( Supplementary Fig. S2A ). Significant induction of ADAM17 activity in response to irradiation was also observed in several other NSCLC cell lines. However, not all cell lines responded to IR with increased ADAM17 activity (Fig. 2C ).
Of note, gene expression of ADAM17 or ADAM10 did not increase in response to IR in A549 and NCI-H125 lung carcinoma cells at the 24 hour and at an early 4 hour time point, respectively ( Fig. 2D and Supplementary Fig. S2B, S2C ).
To acquire full activity, ADAM17 requires its conversion to the mature form lacking its inhibitory prodomain (18, 32) . Reduced amounts of zymogen and concomitantly increased levels of the mature form of ADAM17 could be detected in response to increasing doses of IR ( and not increased levels of ADAM17 gene expression accounts for IR-induced ADAM17 activity.
Targeting of ADAM17 activity sensitizes NSCLC cells for IR
Deregulated shedding of ADAM17 substrates might affect the response of NSCLC cells to IR. We therefore targeted ADAM17 with the ADAM17 inhibitor TMI-005 (Apratastat, 25 μM) and two different ADAM17-directed siRNAs (si-ADAM17#1, 2). Cellular pretreatment with TMI-005 and si-ADAM17#2 strongly downregulated ADAM17 activity, and both targeting approaches significantly decreased the proliferative activity of A549 cells (Fig. 3A) .
si-ADAM17#1 was overall less potent than si-ADAM17#2 to downregulate ADAM17 expression, its shedding and proliferative activity in A549 cells ( Fig. S3D ). Interestingly though cetuximab did not reduce short-term proliferative activity when used as single treatment modality (Fig. 3A) and did not affect clonogenicity on combined treatment with increasing doses of IR in A549 cells (Fig. 3D) Fig. S3E and S3F ).
The proprotein convertase furin mediates IR-induced ADAM17 activation
The proprotein convertase furin proteolytically activates ADAM17 and ADAM10 (35, 36) .
IR-induced ADAM17 conversion and activity was determined in A549 cells pretreated with the irreversible furin inhibitor decanoyl-RVKR-chloromethylketone (Dec-RVKR-CMK).
Dec-RVKR-CMK counteracted IR-induced conversion of pro-ADAM17 to active ADAM17 and kept ADAM17 activity at basal level in irradiated cells ( Fig. 4A and 4B ). The furin inhibitor abrogated IR-enhanced ADAM17 activity also in NCI-H125 cells ( Supplementary   Fig. S4A ). Furthermore Dec-RVKR-CMK sensitized A549 cells for IR and reduced clonogenicity in a supra-additive way (Fig. 4C) . In order to detect a putative upstream IRregulated mechanism, furin gene expression in response to IR was determined by qRT-PCR.
Interestingly increased, IR-dose dependent furin gene expression was observed in A549 cells already 4 hours after irradiation (Fig. 4D) .
To exclude the possibility that furin-inhibitor-based radiosensitization is due to reduced 
To determine downstream effects of ADAM17 activity, ADAM17-mediated ligand shedding was analyzed in irradiated cells pretreated with either the ADAM17 inhibitor TMI-005 or the ADAM17-directed siRNA. Treatment of A549 and NCI-H125 cells with TMI-005 significantly reduced the basal and IR-induced concentrations of the secreted ADAM17-specific substrates ALCAM and Amphiregulin. Likewise, IR-induced ALCAM and Amphiregulin levels were downregulated in supernatants derived from A549 cells, pretreated with the ADAM17-directed ADAM17#2 siRNA (Fig. 5A and 5B).
The EGFR-directed monoclonal antibody cetuximab did not sensitize A549 cells for IR.
Nevertheless we used the EGFR phosphorylation status at tyrosine 1173 (Y1173) as surrogate marker to probe for autocrine receptor activation in response to irradiation and ADAM17 inhibition. Enhanced EGFR phosphorylation was observed in cells 24 hours after irradiation.
On the other hand the EGFR phosphorylation status was strongly reduced at the 24 hour time point in sham-irradiated and irradiated cells pretreated with TMI-005 but only minimally in cells pretreated with cetuximab (Fig. 5C ). Enhanced EGFR phosphorylation over time was observed in control but not in ADAM17-directed siRNA knockdown cells comparing the EGFR phosphorylation status 1, 4 and 24 hours after irradiation (Fig. 5D) . These results correlate with IR-enhanced conditioning of the media and accumulation of autocrine ligands.
To corroborate that ADAM17 regulates an autocrine loop, naïve A549 cells were stimulated with conditioned media (CM) derived from irradiated and sham-irradiated, control and ADAM17-directed siRNA knockdown cells, respectively (Fig. 5E) . A partially enhanced Fig. 5F and Supplementary Fig. S5A ), indicating that ADAM17 increases the threshold for IR-induced senescence. The same senescent phenotype was observed in ADAM17-inhibited, irradiated NCI-H125 cells (Supplementary Fig. S5B ). Inhibition of ADAM17 by either targeting approach did not enhance the overall minimal amount of IR-induced apoptosis in these NSCLC cells (Supplementary Fig. S5C ). In contrast to ADAM17 targeting, cetuximab did not further promote the IR-induced senescence phenotype, which correlates with lack of radiosensitization by cetuximab at the level of the quantitative clonogenic cell survival assay (Fig. 5G, see also Fig. 3D ).
Effect of TMI-005 and IR alone and in combination on the growth of A549-derived tumor xenografts
To determine the efficacy of ADAM17 inhibition in combination with IR in vivo, immunocompromised mice with A549-derived tumor xenografts were treated with the ADAM17 inhibitor TMI-005 (administered orally at 25 mg/kg twice daily for seven consecutive days, day 1-7) and locally irradiated during 3 consecutive days (1 Gy, days 3-5) (Fig. 6B) Fig. S6B-S6D ).
Research. Collectively, these results indicate that combined treatment of TMI-005 and IR exerts a supraadditive tumor growth delay in these NSCLC cell-derived tumor xenografts and leads to better tumor control with minimal normal tissue toxicity.
Discussion
Increased expression of ADAM17 significantly correlates with enhanced aggressivity of NSCLC on the clinical level (27, 28) , and ADAM17-shedded substrates are cytoprotective against different anti-tumor agents, as demonstrated in multiple tumor cell systems (4, 13, 37) .
Here, we identified that IR promotes furin-mediated activation of ADAM17 with increased shedding of ADAM17 substrates and thereby contributes to an IR-induced stress response in NSCLC. Subsequently, direct inhibition of ADAM17 lowered an intrinsic and treatmentinduced threshold and strongly enhanced the efficacy of IR in vitro and in vivo. These results represent a promising rationale for the clinical assessment of a combined treatment modality of ADAM17 inhibitors with irradiation in NSCLC patients. We identified ADAM17 as direct target for radiosensitization based on our semiquantitative antibody array approach, screening for factors differentially secreted in response to irradiation. These factors were quantitatively validated by ELISA across a panel of NSCLC cell lines and could subsequently also be monitored in the blood serum derived from mice with locally irradiated tumors. As such, serum detection of ADAM17 substrates in irradiated tumor patients might also serve as a relevant, minimally invasive endpoint on the clinical level.
An increase of specific ADAM17 substrates after irradiation was previously detected on the preclinical and clinical level without investigating the underlying mechanism mediating radiation-induced secretion. For example, upregulated CXCL16 levels were observed in breast cancer cell lines in response to IR (38) and increased TGF-α levels were detected after irradiation in hormone-refractory prostate cancer patients (4) . Increased ADAM17 substrate While EGFR-directed agents, also in combination with radiation therapy, are a promising treatment strategy, many tumors rapidly acquire resistances during the course of treatment.
Alternative concepts suggest combination therapies of EGFR inhibition in combination with
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inhibitors for other HER family receptors (44, 45) . A major advantage of targeting ADAM17 includes its broad spectrum of downregulated substrates for all different HER family and other RTKs, which might increase the potency of direct ADAM17 targeting as compared to the inhibition of individual receptors.
A recent phase III clinical trial for locally advanced NSCLC investigated both radiotherapy dose escalation and the combined use of cetuximab, which both failed to further improve treatment outcome (21) . Lack of responsiveness to EGFR inhibition might be linked to the Kras mutational status, however the specific role of Kras in NSCLC for the sensitivity to EGFR inhibitors alone and in combination with radiotherapy is still controversial (46) (47) (48) (49) . We used the EGFR phosphorylation status as surrogate marker to determine shedding of ADAM17-mediated EGFR ligands. Interestingly, irradiation induced prolonged activation of EGF-RTK activity, which correlated with increased IR-mediated ADAM17 activation. EGF-RTK activity was strongly counteracted by pharmacologic inhibition of ADAM17 or in ADAM17 knockdown cells with subsequent downregulation of EGFR ligand shedding. In contrast the EGFR-directed antibody cetuximab only partially reduced prolonged, IRdependent RTK activation and did not sensitize for IR. Thus, ADAM17 might be a superior target for radiosensitization due to the inhibition of multiple downstream processes, but also pharmacodynamically due to sustained inhibition of ligand shedding and thereby reducing an IR-induced, acquired resistance mechanism.
Since NSCLC is also treated with radiochemotherapy regimens including classic chemotherapeutics e.g. cisplatinum and taxanes, it will be important to probe in detail inhibition of these pleiotropic effects by ADAM17 inhibition in combination with chemo-radiation for NSCLC. Our in vivo results demonstrate the potency of the combined treatment modality of the ADAM17 inhibitor TMI-005 and IR. TMI-005 significantly reduced the tumor proliferative capacity and exerted a supra-additive tumor growth delay in combination with IR. TMI-005, also known as Apratastat is an orally bioavailable small-molecular inhibitor of ADAM17, which was initially designed for the treatment of rheumatoid arthritis (RA) as it inhibits TNF-α release (50, 51) . Adequate ADAM17-inhibitory clinical dosing for TMI-005 was established in a long-term, randomized phase II study with up to 390 RA patients (52).
Though, the clinical program with TMI-005 and other closely related derivatives were stopped due to lack of efficacy in RA, related to constitutive activation of the TNF-α receptor on immunological cells, but not due to toxicity reasons (50, 53) . Based on its low toxicity profile and target relevance independent of TNF-α, TMI-005 and other new classes of ADAM17 inhibitors have thus a strong rational for repositioning in NSCLC as part of a combined treatment modality with radiotherapy.
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(F) Representative images of immunohistochemical staining of ADAM17, ALCAM, Amphiregulin and Ki-67 in response to treatments. Scale bar 100 μm. **P<0.01, ***P<0.001.
